Time for targeted therapies in acute respiratory distress syndrome? Understanding every single piece of the puzzle

Critical Care Medicine

Volumn 46, Issue 5, 2018, Pages 834-835

  Gaudet, Alexandre ^a,b   Poissy, Julien ^a,c   Mathieu, Daniel ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

acute respiratory distress syndrome; C5a; IFX 1; paraquat; targeted therapy

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; IFX 1; SURFACTANT PROTEIN A; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; PARAQUAT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DIAPEDESIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HYPEREMIA; LEUKOCYTE ADHERENCE; LUNG FUNCTION; MACROPHAGE; MOLECULARLY TARGETED THERAPY; NEUTROPHIL; NONHUMAN; PARAQUAT POISONING; PRIORITY JOURNAL; UPREGULATION; LUNG EDEMA; LUNG INJURY;

HUMANS; LUNG INJURY; PARAQUAT; PULMONARY EDEMA; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85054127979     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002987     Document Type: Editorial

References (11)

1. Famous KR, Delucchi K, Ware LB, et al; ARDS Network: Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017; 195:331-338
2. Calfee CS, Delucchi K, Parsons PE, et al; NHLBI ARDS Network: Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014; 2:611-620
3. Bosmann M, Ward PA: Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 2012; 946:147-159
4. Wang R, Xiao H, Guo R, et al: The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect 2015; 4:e28
5. Sun S, Zhao G, Liu C, et al: Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis Off Publ Infect Dis Soc Am 2015; 60:586-595
6. Sun S, Zhao G, Liu C, et al: Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol 2013; 49:221-230
7. Sun S, Wang H, Zhao G, et al: Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol 2011; 45:834-842
8. Sun S, Jiang Y, Wang R, et al: Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application. Crit Care Med 2018; 46:e419-e425
9. Calfee CS, Ware LB, Eisner MD, et al; NHLBI ARDS Network: Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089
10. Orbegozo D, Rahmania L, Irazabal M, et al: Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome. Ann Intensive Care 2017; 7:93
11. Palud A, Parmentier-Decrucq E, Pastre J, et al: Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine 2015; 73:213-218